News stories about Orthofix International N.V. (NASDAQ:OFIX) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Orthofix International N.V. earned a news impact score of 0.02 on Accern’s scale. Accern also gave media headlines about the medical device company an impact score of 44.868640418559 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- learn details of the Latin America artificial organs and bionics industry (whatech.com)
- Medical bionic implants Market – Competitive outlook to stay abreast on the key trends impacting this market by 2022. (medgadget.com)
- Reviewing Orthofix International N.V. (OFIX) and Its Rivals (americanbankingnews.com)
- $101.60 Million in Sales Expected for Orthofix International N.V. (OFIX) This Quarter (americanbankingnews.com)
- North America Artificial Organs and Bionics Industry size to hit USD 9.48 Billion by 2021 (reports.pr-inside.com)
A number of brokerages have recently weighed in on OFIX. Zacks Investment Research downgraded Orthofix International N.V. from a “strong-buy” rating to a “hold” rating in a report on Wednesday. BidaskClub upgraded Orthofix International N.V. from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Jefferies Group LLC reiterated a “buy” rating and issued a $55.00 price target (up from $50.00) on shares of Orthofix International N.V. in a report on Thursday, August 10th. TheStreet upgraded Orthofix International N.V. from a “c+” rating to a “b-” rating in a report on Tuesday, August 8th. Finally, BTIG Research began coverage on Orthofix International N.V. in a report on Wednesday, June 21st. They issued a “buy” rating and a $52.00 price target for the company. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $52.75.
Orthofix International N.V. (NASDAQ:OFIX) opened at 49.08 on Thursday. The company’s 50-day moving average price is $48.74 and its 200-day moving average price is $44.40. The company has a market capitalization of $891.78 million, a P/E ratio of 114.94 and a beta of 0.20. Orthofix International N.V. has a 52 week low of $32.51 and a 52 week high of $51.09.
Orthofix International N.V. (NASDAQ:OFIX) last announced its quarterly earnings data on Monday, August 7th. The medical device company reported $0.42 EPS for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.01. Orthofix International N.V. had a return on equity of 9.96% and a net margin of 1.88%. The company had revenue of $108.90 million during the quarter, compared to the consensus estimate of $102.94 million. During the same quarter last year, the company earned $0.41 EPS. The company’s quarterly revenue was up 4.6% on a year-over-year basis. On average, equities analysts forecast that Orthofix International N.V. will post $1.56 EPS for the current fiscal year.
In other news, CFO Rice Doug sold 7,353 shares of the stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $49.46, for a total value of $363,679.38. Following the completion of the transaction, the chief financial officer now directly owns 44,743 shares of the company’s stock, valued at approximately $2,212,988.78. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Raymond Fujikawa sold 6,364 shares of the stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $47.06, for a total value of $299,489.84. Following the completion of the transaction, the insider now directly owns 31,084 shares of the company’s stock, valued at $1,462,813.04. The disclosure for this sale can be found here. Over the last three months, insiders sold 23,406 shares of company stock valued at $1,138,531. 5.60% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Orthofix International N.V. (OFIX) Stock Price” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://sportsperspectives.com/2017/10/12/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-orthofix-international-n-v-ofix-stock-price.html.
Orthofix International N.V. Company Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.